Prior to COVID Mania, Novavax and its competitors had never brought a product to market
On Tuesday, the FDA’s advisory committee — a concoction of massively corrupt individuals who entertain a plethora of conflicts of pharmaceutical interests — unanimously voted to clear Novavax’s COVID injection on the path to FDA emergency use authorization.
This “expert” panel, which again and again has presented a green light for mRNA injections for young children, has concluded that Novavax’s product is a worthy COVID vaccine. Why? Because they say so.
Should the Maryland-based company receive FDA clearance, they will become the 4th company in the U.S. — and the first since February 2021 — to enter the COVID vaccine government gravy train.
Don’t expect Novavax to be the cure for a coronavirus that you were looking for. There’s several reasons why you should expect this product to work as poorly as the rest of them.
Novavax was designed for the original COVID strain
The Novavax COVID-19 shot was designed in early 2020 and has not been updated to combat any current variants. This is also true for the Pfizer and Moderna shots, which were designed on an mRNA platform, and never updated.
Novavax is not a “traditional” vaccine
Perhaps the most prevalent marketing behind Novavax advances the claim that the product is a more traditional vaccine, akin to an inactivated vaccine that is associated with a Flu shot.
This idea is presented to the public with the hopes that “vaccine hesitant” individuals will take Novavax shots instead of the ostensible more edgy mRNA shots.
But in reality, the Novavax shot does not contain the traditional inactivated virus. It is usually defined as a subunit protein shot.
@UnWokeCEO @kerpen The Novavax vaccine on which everyone is focused presents a modified spike protein to the immune system, not an inactivated virus. This avoids the RNA/DNA genetic therapy issue, but not the risk of toxicity from the spike protein itself.
It’s not mRNA, but it’s also not traditional or “normal” in the sense that most understand.
Novavax has never brought a product to market
Similar to their competitors in Moderna and BioNTech, Novavax has never brought a product to market. That didn’t stop the government from investing $1.6 billion in taxpayer funds in the company.
Novavax closes in on Covid triumph after 33 years of failure Subscribe to read | Financial TimesNews, analysis and comment from the Financial Times, the worldʼs leading global business publicationon.ft.com
In its 33 year history, Novavax has attempted to bring a handful of products to market, including Ebola and Flu vaccines, but the company never succeeded prior to COVID Mania. They have zero track record of success, safety, and/or efficacious products.
The Novavax shot, like mRNA COVID injections, has a demonstrated increased risk for heart inflammation
Myocarditis was observed in several of the trial participants within 2 weeks of injection.
Stat News reports: “Five of the cases of myocarditis and pericarditis in the Novavax trial were reported within two weeks of vaccination. One case may have been caused by Covid, not the vaccine, but there were no clear alternative explanations for the other cases. Four cases of heart inflammation occurred in young men.”
Myocarditis is not just a Novavax side effect. It remains a major issue among the experimental mRNA injections sold by Pfizer and Moderna.
Much to the delight of depraved Pfizer and Moderna executives, if the myocarditis narrative can stick to Novavax, it could sink their potential market share. After the FDA advisory committee published their concerns, the stock market reacted negatively to Novavax, despite the green light for an FDA emergency use authorization.
“US FDA issues warning of myocarditis for Novavax’s COVID vaccine, suggesting a common factor being the spike protein across all vaccine platforms.” Via @Mod_Disc All Roads Lead to Spike (Protein)US FDA issues warning of myocarditis for Novavax’s COVID vaccine, suggesting a common factor being the spike protein across all vaccine platforms.moderndiscontent.substack.com
Novavax and the FDA panel has already acknowledged that two doses of the Novavax shot will not be enough to “protect” people from a coronavirus. Therefore, repeated boosting is already being discussed as a probable path forward for this latest pharmaceutical.
There is no trial data on Omicron variant
The shot was developed over two years ago, and it has not been tested for Omicron. The FDA said in a statement:
“Relevant data to assess effectiveness of NVX-CoV2373 (Novavax shot) against the Omicron variant and sublineages, including observational data from use in other countries where the vaccine has been deployed, are currently unavailable.”
And yet, the stellar advisory committee approved it anyway.
As Forbes reports, even Novavax has acknowledged that the shot may not work as well for the mutation that is actually present today in 2022. The report says:
“Novavax said its vaccine showed ‘cross-reactive immune response’ against omicron and other coronavirus variants, though it noted that the neutralizing response for the omicron variant was four times lower than for the original coronavirus.”
Not a cure.
The Novavax shot has been approved in several countries already and their inhabitants have not become immune from COVID-19 or cured of a disease.
Although there are dozens of different COVID “vaccines” available throughout the world, none have demonstrated a discernible difference in outcomes. In reality, this is just another questionable pharmaceutical product that joins the endless and continuing list of questionable pharmaceutical products on the market.